Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 2/2021

Open Access 01-02-2021 | Infliximab | Educational Review

Renal involvement in paediatric inflammatory bowel disease

Author: Mohamed Mutalib

Published in: Pediatric Nephrology | Issue 2/2021

Login to get access

Abstract

Inflammatory bowel disease (IBD), which includes Crohn’s disease, ulcerative colitis and inflammatory bowel disease unclassified, is a chronic inflammatory disorder that predominantly affects the gastrointestinal (GI) tract and has a rising incidence in both children and adults. Symptoms are caused by inappropriate inflammatory response triggered by interaction between the environment, gut microbiome and host immune system in a genetically susceptible individual. Extranintestinal manifestations of IBD are common and can affect any body system outside the gut; they can precede or run parallel to GI inflammation. Renal involvement in IBD is uncommon and can be part of extraintestinal manifestation or metabolic complications of IBD. Many medications used to treat IBD can cause renal damage. Renal manifestation in children with IBD can range from asymptomatic biochemical abnormalities to variable stages of renal impairment with significant morbidity and even mortality burden.
Literature
1.
de Souza HS, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13:13–27PubMedCrossRef
2.
Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (2014) ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795–806PubMedCrossRef
3.
Ott C, Scholmerich J (2013) Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 10:585–595PubMedCrossRef
4.
Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U, Navarini A, van der Meulen-de Jong AE, Maul J, Katsanos K, Kagramanova A, Greuter T, González-Lama Y, van Gaalen F, Ellul P, Burisch J, Bettenworth D, Becker MD, Bamias G, Rieder F (2019) The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 13:541–554PubMedCrossRef
5.
Rothfuss KS, Stange EF, Herrlinger KR (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12:4819–4831PubMedPubMedCentralCrossRef
6.
Ambruzs JM, Larsen CP (2018) Renal manifestations of inflammatory bowel disease. Rheum Dis Clin North Am 44:699–714PubMedCrossRef
7.
Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S (2011) Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 17:1034–1045PubMedCrossRef
8.
Ricart E, Sandborn WJ (2003) Extraintestinal manifestations of inflamamtory bowel disease. In: Cohen RD (ed) Inflammatory Bowel Disease. Clinical Gastroenterology. Humana Press, Totowa
9.
Ambruzs JM, Walker PD, Larsen CP (2014) The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 9:265–270PubMedCrossRef
10.
McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B (2002) Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 89:835–841PubMedCrossRef
11.
Bianchi L, Gaiani F, Bizzarri B, Minelli R, Cortegoso Valdivia P, Leandro G, Di Mario F, De’ Angelis GL, Ruberto C (2018) Renal lithiasis and inflammatory bowel diseases, an update on pediatric population. Acta Biomed 89:76–80PubMed
12.
Parks JH, Worcester EM, O’Connor RC, Coe FL (2003) Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 63:255–265PubMedCrossRef
13.
Katsanos K, Tsianos EV (2002) The kidneys in inflammatory bowel disease. Ann Gastroenterol 15:41–52
14.
Ganji-Arjenaki M, Nasri H, Rafieian-Kopaei M (2017) Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis. J Nephropathol 6:264–269PubMedPubMedCentralCrossRef
15.
Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, Gozzetti G, Miglioli M (1993) Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc 7:371–379PubMed
16.
Kane S (2006) Urogenital complications of Crohn’s disease. Am J Gastroenterol 101(12 Suppl):S640–S643PubMed
17.
Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT (1998) Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 93:504–514PubMedCrossRef
18.
Johnson E, Vu L, Matarese LE (2018) Bacteria, bones, and stones: managing complications of short bowel syndrome. Nutr Clin Pract 33:454–466PubMedCrossRef
19.
Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF (2001) Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 15:363–369PubMedCrossRef
20.
Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ (2001) Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 15:1131–1137PubMedCrossRef
21.
Kreisel W, Wolf LM, Grotz W, Grieshaber M (1996) Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 8:461–468PubMed
22.
Velciov S, Gluhovschi G, Sporea I, Trandafirescu V, Petrica L, Bozdog G, Gluhovschi C, Bob F, Gădălean F, Buzaş R, Bobu M, Voicu L (2011) Asymptomatic urinary anomalies, hematuria and proteinuria, in patients with inflammatory bowel disease. Preliminary study. Rom J Intern Med 49:113–120PubMed
23.
Corica D, Romano C (2015) Renal involvement in inflammatory bowel diseases. J Crohns Colitis 10:226–235PubMedCrossRef
24.
Filiopoulos V, Trompouki S, Hadjiyannakos D, Paraskevakou H, Kamperoglou D, Vlassopoulos D (2010) IgA nephropathy in association with Crohn’s disease: a case report and brief review of the literature. Ren Fail 32:523–527PubMedCrossRef
25.
Shaer AJ, Stewart LR, Cheek DE, Hurray D, Self SE (2003) IgA antiglomerular basement membrane nephritis associated with Crohn’s disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis 41:1097–1109PubMedCrossRef
26.
Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196PubMedPubMedCentralCrossRef
27.
Freedman BI, Spray BJ, Heise ER (1994) HLA associations in IgA nephropathy and focal and segmental glomerulosclerosis. Am J Kidney Dis 23:352–357PubMedCrossRef
28.
29.
Coppo R (2018) The gut–kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr Nephrol 33:53–61PubMedCrossRef
30.
31.
Suárez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC (2017) T cells and autoimmune kidney disease. Nat Rev Nephrol 13:329–343PubMedCrossRef
32.
Ridder RM, Kreth HW, Kiss E, Gröne HJ, Gordjani N (2005) Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl. Pediatr Nephrol 20:1349–1351PubMedCrossRef
33.
Jang HM, Baek HS, Kim JE, Kim JY, Lee YH, Cho HY, Choe YH, Kang B, Choe BH, Choi BS, Cho MH (2018) Renal involvement in children and adolescents with inflammatory bowel disease. Korean J Pediatr 61:327–331PubMedPubMedCentralCrossRef
34.
Marcus SB, Brown JB, Melin-Aldana H, Strople JA (2008) Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in Children. J Pediatr Gastroenterol Nutr 46:338–341PubMedCrossRef
35.
Bastard JP, Fellahi S, Regeniter A, Capeau J, Ronco P, Plaisier E (2019) Aside from acute renal failure cases, are urinary markers of glomerular and tubular function useful in clinical practice? Clin Biochem 65:1–6PubMedCrossRef
36.
Muhammad HSS, Peters C, Casserly LF, Dorman AM, Watts M (2010) Relapsing tubulointerstitial nephritis in an adolescent with inflammatory bowel disease without aminosalicylate exposure. Clin Nephrol 73:250–252CrossRef
37.
Elloumi H, Ben Slama A, Arfaoui D, Ghouma M, Sfar S, Ajmi S (2006) Renal amyloidosis complicating Crohn’s disease: report of two cases and review of literature. Tunis Med 84:253–255PubMed
38.
Sattianayagam PT, Gillmore JD, Pinney JH, Gibbs SD, Wechalekar AD, Gilbertson JA, Rowczenio D, Hawkins PN, Lachmann HJ (2013) Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci 58:1689–1697PubMedCrossRef
39.
40.
Kirschner BS, Samowitz WS (1986) Secondary amyloidosis in Crohn’s disease of childhood. J Pediatr Gastroenterol Nutr 5:816–821PubMedCrossRef
41.
Cucino C, Sonnenberg A (2001) The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn’s disease. Am J Gastroenterol 96:2107–2112PubMedCrossRef
42.
Ebert EC, Nagar M, (2008) Gastrointestinal Manifestations of Amyloidosis. Am J Gastroenterol 103(3):776–787
43.
Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, Dias JA, Bronsky J, Braegger CP, Cucchiara S, de Ridder L, Fagerberg UL, Hussey S, Hugot JP, Kolacek S, Kolho KL, Lionetti P, Paerregaard A, Potapov A, Rintala R, Serban DE, Staiano A, Sweeny B, Veerman G, Veres G, Wilson DC, Ruemmele FM, European Crohn's and Colitis Organization; European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (2012) Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 55:340–361PubMedCrossRef
44.
Christensen LA, Fallingborg J, Jacobsen BA, Abildgaard K, Rasmussen HH, Hansen SH, Rasmussen SN (1994) Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 8:289–294PubMedCrossRef
45.
Muller AF, Stevens PE, Mcintyre AS, Ellison H, Logan RF (2005) Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 21:1217–1224PubMedCrossRef
46.
Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J (2008) Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol Hepatol 31:477–484PubMedCrossRef
47.
de Jong DJ, Tielen J, Habraken CM, Wetzels JF, Naber AH (2005) 5-Aminosalicylates and effects on renal function in patients with Crohn’s disease. Inflamm Bowel Dis 11:972–976PubMedCrossRef
48.
Uslu N, Demir H, Saltik-Temizel IN, Topaloğlu R, Gürakan F, Yüce A (2007) Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. Dig Dis Sci 52:2926–2929PubMedCrossRef
49.
Co ML, Gorospe EC (2013) Pediatric case of mesalazine-induced interstitial nephritis with literature review. Pediatr Int 55:385–387PubMedCrossRef
50.
Bir K, Herzenberg AM, Carette S (2006) Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener’s granulomatosis. J Rheumatol 33:185–187PubMed
51.
Meys E, Devogelaer JP, Geubel A, Rahier J, Nagant de Deuxchaisnes C (1992) Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity. J Rheumatol 19:807–809PubMed
52.
Danese S, Vuitton L, Peyrin-Biroulet L (2015) Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 12:537–545PubMedCrossRef
53.
Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD (2005) Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400–1406PubMedCrossRef
54.
Haake H, Koneke J, Amann K, vom Dahl J, Janssen U (2007) Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin (Munich) 102:852–857CrossRef
55.
Neale TJ, Rüger BM, Macaulay H, Dunbar PR, Hasan Q, Bourke A, Murray-McIntosh RP, Kitching AR (1995) Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 146:1444–1454PubMedPubMedCentral
56.
Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383–2390PubMedCrossRef
57.
Saka Y, Taniguchi Y, Nagahara Y, Yamashita R, Karasawa M, Naruse T, Watanabe Y (2017) Rapidly progressive lupus nephritis associated with golimumab in a patient with systemic lupus erythematosus and rheumatoid arthritis. Lupus 26:447–448PubMedCrossRef
58.
Baumgart DC, MacDonald JK, Feagan B (2008) Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 3:CD007216
59.
Hosoi K, Arai K, Matsuoka K, Shimizu H, Kamei K, Nakazawa A, Shimizu T, Tang J, Ito S (2017) Prolonged tacrolimus for pediatric gastrointestinal disorder: double-edged sword? Pediatr Int 59:588–592PubMedCrossRef
60.
Watson S, Pensabene L, Mitchell P, Bousvaros A (2011) Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 17:22–29PubMedCrossRef
61.
Baumgart DC, Wiedenmann B, Dignass AU (2003) Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 17:1273–1281PubMedCrossRef
62.
Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG (2017) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66:839–851PubMedCrossRef
63.
Bailly E, Von Tokarski F, Beau-Salinas F, Picon L, Miquelestorena-Standley E, Rousseau G, Jonville-Bera AP, Halimi JM (2018) Interstitial nephritis secondary to vedolizumab treatment in crohn disease and safe rechallenge using steroids: a case report. Am J Kidney Dis 71:142–145PubMedCrossRef
Metadata
Title
Renal involvement in paediatric inflammatory bowel disease
Author
Mohamed Mutalib
Publication date
01-02-2021
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 2/2021
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-019-04413-5

Other articles of this Issue 2/2021

Pediatric Nephrology 2/2021 Go to the issue

Educational Review

Protein energy wasting; what is it and what can we do to prevent it?

Clinical Quiz

Acute kidney injury in an adolescent: Answers

Original Article

Native vs. active vitamin D in children with chronic kidney disease: a cross-over study

Original Article

The need for hemodialysis is associated with increased mortality in mechanically ventilated children: a propensity score–matched outcome study

Clinical Quiz

Acute kidney injury in an adolescent: Questions

Original Article

Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis